{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:58Z","timestamp":1761520198035,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clcc.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T14:48:38Z","timestamp":1562078918000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Phase II Study of Capecitabine\/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal"],"prefix":"10.1016","volume":"18","author":[{"given":"Cathy","family":"Eng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre A.","family":"J\u00e1come","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajnan","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Rodriguez-Bigas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Skibber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salil","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Ohinata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2019.06.003_bib1","first-page":"7","article-title":"Cancer Statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2019.06.003_bib2","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2019.06.003_bib3","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin vs. fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (Act II): a randomised, phase 3, open-label, 2\u00a0\u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: the Surveillance, Epidemiology, and End Results Experience, 1973-2000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"year":"2018","series-title":"Seer Cancer Statistics Review, 1975-2015","author":"Noone","key":"10.1016\/j.clcc.2019.06.003_bib6"},{"key":"10.1016\/j.clcc.2019.06.003_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.clcc.2019.06.003_bib8","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine vs. intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib9","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial Accord 12\/0405-Prodige 2","volume":"28","author":"G\u00e9rard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2006.08.3675","article-title":"Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer","volume":"25","author":"R\u00f6del","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib11","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","article-title":"Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the star-01 randomized phase III trial","volume":"29","author":"Aschele","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","article-title":"Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin vs. fluorouracil alone in locally advanced rectal cancer: initial results of the german Cao\/Aro\/Aio-04 randomised phase 3 trial","volume":"13","author":"R\u00f6del","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib13","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1200\/JCO.2003.02.505","article-title":"Phase I\/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer","volume":"21","author":"R\u00f6del","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib14","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08cb (Alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.06.003_bib16","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","article-title":"Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project Trial R-04","volume":"32","author":"O\u2019Connell","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib17","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.2016.66.6198","article-title":"Modified FOLFOX6 with or without radiation vs. fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese Fowarc multicenter, open-label, randomized three-arm phase III trial","volume":"34","author":"Deng","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib18","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.06.003_bib19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.03.022","article-title":"Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer","volume":"98","author":"Goodman","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2019.06.003_bib20","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","article-title":"Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort","volume":"101","author":"Jones","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2019.06.003_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (Act II): a post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib22","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized Unicancer Accord 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib23","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib24","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the Unicancer Accord 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium Trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib26","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.ejca.2009.06.020","article-title":"Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)","volume":"45","author":"Matzinger","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2019.06.003_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12029-015-9790-4","article-title":"Phase II study of capecitabine in substitution of 5-Fu in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal","volume":"47","author":"Oliveira","year":"2016","journal-title":"J\u00a0Gastrointest Cancer"},{"key":"10.1016\/j.clcc.2019.06.003_bib28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0360-3016(96)00146-0","article-title":"Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study","volume":"35","author":"Martenson","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2019.06.003_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0959-8049(02)00377-5","volume":"39","author":"Bosset","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2019.06.003_bib30","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.ijrobp.2011.02.042","article-title":"Long-term follow-up of a phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292)","volume":"81","author":"Chakravarthy","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2019.06.003_bib31","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.06.003_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMc0911925","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"362","author":"Cunningham","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.06.003_bib33","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.06.003_bib34","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox vs. gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.06.003_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX vs. fluorouracil and cisplatin in patients with oesophageal cancer (Prodige5\/Accord17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002819302129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002819302129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:03Z","timestamp":1761519963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002819302129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1533002819302129"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2019.06.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Study of Capecitabine\/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}